Selective S1P1 and S1P5 Modulators for Subtype Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions mediated by sphingosine-1-phosphate receptor activation lack effective modulators that can selectively target specific receptor subtypes, such as S1P1 and S1P5, to address physiological imbalances.
Innovation Solution
Development of compounds that act as selective modulators, particularly S1P1 and S1P5 agonists, including orthosteric and allosteric agonists, which integrate with the sphingosine-1-phosphate receptor to activate signal transduction, offering selective action on these subtypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current treatments are used for conditions mediated by sphingosine-1-phosphate receptor activation, then general treatment approach is maintained, but selective targeting of specific receptor subtypes (S1P1 and S1P5) is lacking
Solution Approach 1:
The patent segments the sphingosine-1-phosphate receptor family into distinct subtypes (S1P1, S1P2, S1P3, S1P4, S1P5) and develops compounds that selectively target specific subtypes. The compounds are designed to differentiate between receptor subtypes through specific molecular interactions, enabling selective modulation of S1P1 and S1P5 receptors while leaving other subtypes unaffected.
Solution Approach 2:
The patent applies local quality by creating compounds with specific structural features that confer selectivity for particular receptor subtypes. The molecular structure of the compounds includes specific functional groups and spatial arrangements that match the binding pockets of S1P1 and S1P5 receptors, providing localized selective action rather than broad-spectrum modulation.
2Measurement precision
If selective modulators are developed to target specific receptor subtypes, then treatment precision is improved, but compound complexity increases
Solution Approach 1:
The patent employs parameter changes by systematically varying molecular parameters such as substituent groups, chain lengths, and functional group positions in the compound structures. These parameter variations are optimized to achieve maximum selectivity for target receptor subtypes while maintaining reasonable structural complexity for drug development.
Data Source
AI summary
Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable salt, homolog, hydrate or solvate thereof, wherein R is as defined herein. Such compounds serve as modulators of the sphingosine-1-phosphate receptor, and have utility for treatment of a malcondition for which activation of this receptor is medically indicated.